INVA stock forecast
Our latest prediction for Innoviva, Inc.'s stock price was made on the May 21, 2018 when the stock price was at 14.47$.
In the short term (2weeks), INVA's stock price should outperform the market by 0.29%. During that period the price should oscillate between -4.93% and +5.95%.
In the medium term (3months), INVA's stock price should outperform the market by 2.39%. During that period the price should oscillate between -13.20% and +18.05%.Get email alerts
Create a solid portfolio with INVA
About Innoviva, Inc.
Innoviva, Inc. is engaged in the development, commercialization, and financial management of bio-pharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate; and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.
At the moment the company generates 251M USD in revenues.
On its last earning announcement, the company reported a profit of 1.69$ per share.
The book value per share is -1.55$
Three months stock forecastMay 21, 2018
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|